NCOA2 and neoplasm: In addition, a recent report showed that imatinib, a tyrosine kinase inhibitor (TKI), significantly reduced tumor growth in the HEY1-NCOA2 fusion-driven cellular model as well as in MCS patient–derived xenograft models.